Tirzepatide's dual receptor mechanism How tirzepatide works: Dual GIP/GLP-1 receptor agonist Single molecule, two pathways GIP (glucose-dependent insulinotropic polypeptide) + GLP-1 Weekly subcutaneous injection FDA approved for diabetes and obesity GIP pathway effects: Enhances insulin secretion Improves insulin sensitivity Promotes fat metabolism Reduces inflammation Works synergistically with GLP-1 GLP-1 pathway effects: Suppresses appetite (central brain effects) Slows gastric emptying (moderate) Increases satiety Reduces glucagon Improves glucose control Combined tirzepatide results: 15-22% average body weight loss (monotherapy) Superior to semaglutide (GLP-1 alone) Well-tolerated in trials Approved and available See our tirzepatide dosing guide , semaglutide vs tirzepatide , and peptides for weight loss at SeekPeptides
Assessment, prevention and treatment strategies are largely extrapolated from data from HIV-uninfected people
Semaglutide may be associated with reproductive risk and preconceptual planning is recommended
It helps to balance oil production, improve skin elasticity and protect the skin barrier
You'll be offered vials of molecules with funky names that sound like exoplanets: GHK-CU, CJC12-95, Thymosin Beta-4
PFAS forever chemicals accumulate in blood and tissue and resist normal clearance